Our vision is for every therapeutic discovery to be enhanced by our solutions.
Through our expertise and unique heritage, we provide innovative and high-quality solutions to researchers around the world.
By doing so we enable ground-breaking medical discovery, better diagnosis and patient outcomes.
HistoCyte Laboratories offers high quality, reproducible and cost-effective analyte control material for same-slide use in histopathology. Current products include controls for PD-L1, Her2, ER, PR, EML4-ALK, ROS1, NPM-ALK, HPV and p16, with many more in development. Our latest controls for mismatch repair (MMR) consist of four different cell lines with loss of and intact expression for MLH1, PMS2, MSH2 and MSH6.
Formed in 2014, HistoCyte Laboratories has established a significant presence in important markets such as the UK and USA. The company has a strong growth trajectory that is expected to accelerate as acceptance of cell line controls increases rapidly.
evitria is an established, global antibody expression service provider located in Zurich, Switzerland. They specialize in CHO-based transient expression of antibodies - including bispecific and fusion antibodies - and other proteins. Since its inception in 2010, evitria has been singularly focused on transient expression of recombinant antibodies in CHO cells. This long-standing and deep focus allows the company to deliver antibodies of exceptional quality with outstanding service levels with respect to turnaround time and material quantity. With a track record of more than 75,000 transfections performed and more than 12,000 antibody-based molecules purified, evitria is a trusted partner for full outsourcing of antibody production for research purposes, to manage capacity bottlenecks, or to pursue single projects.